MEET YOUR WORLD CLASS TEAM
I am Managing Partner at Partners4Access, the global access experts for orphan drugs. I am heavily involved in advising orphan drug clients on price and market access strategies, with the ultimate goal of optimizing their launch. My 20 year career spans various pharmaceutical therapy areas and medical devices. During my time in industry I worked on several key product launches in both strategic planning and implementation. Managing global, regional and local teams has certainly helped me advise clients how to successfully face the real-life challenges in today’s biotech world.
I am the Performance Excellence Specialist at Partners4Access. I worked in global and European pricing and market access for over 20 years.
Following the acquisition of PriceSpective by ICON in 2012, I was successively European Head and Global Head of the Pricing and Market Access consulting team. I led consulting projects for a very large number of large, medium and small biopharma companies, across a wide range of therapy areas and all phases of development, with a focus on in-licensing evaluations, phase 3 planning, launch pricing and market access and loss of exclusivity planning. In addition I led projects advising clients on internal process and infrastructure.
During my industry tendure, I worked at GSK where responsibilities included pricing and reimbursement strategy for pipeline products, price management of marketed products and managing the in-house price database. Stuart has a degree in mathematics from Oxford University and a master in Operational Research.
I am Executive Director, Business Development at Partners4Access. In my role I ensure Orphan Drug Companies develop successful global market access strategies. My experience has been gained over 25 years both in the pharmaceutical industry, and in consulting services. During this time, I led National, European and Global projects in sales, marketing, business development, M&A, pricing and strategic market access initiatives.
I am a Senior Analyst at Partners4Access, as such I am involved in developing price and market access strategies for orphan drug clients. My expertise includes building market access and policy strategies for Life Science clients across various therapy areas. Previously, I worked in-house for a pharmaceutical company and for a trade association representing small and medium sized bio tech companies and as well as in consulting in global and regional level.
I am a Senior Analyst at Partners4Access with a decade experience in the pharmaceutical and healthcare industry. My primary focus is on pricing and reimbursement barriers in healthcare systems. I worked on a variety of projects on pricing potential, value story development and payer landscapes and on several emerging market country projects. In my previous role I analysed corporate strategies, market access barriers, landscape assessments, and presented key actionable recommendations to pharmaceutical and medical device firms. I hold a Bachelor of Science degree in Zoology from the University of Mumbai and a Masters in International Finance, from Middlesex University, in London with a focus on econometric modelling on the pharmaceutical industry. She has also completed certificate courses on Health Economics and Cost-Effectiveness Analysis from the University of Oxford’s HERC (Health Economics Research Centre).
I am a Senior Analyst at Partners4Access with experience in competitive landscape assessments, stakeholder mapping and commercial analysis for the pharmaceutical industry. Prior to joining P4A, I worked as an analyst at one of the industry’s leading competitive intelligence firms.
I covered multiple therapy areas including, but not limited to, meningococcal vaccines, immuno-oncology, ophthalmology and rare diseases. I have an undergraduate degree in International Business Studies and a postgraduate degree in International Healthcare management. I am fluent English and Arabic
I am an intern at Partners4 Access. I am currently completing a Master in Bioscience Enterprise at Cambridge University. As part of the dissertation project, I am aiming to define future roles of economic methods in health technology assessments and determine the implications for optimal market access strategies of P4A’s clients. I have previously worked for a global biotechnology company and has also attained a Bachelors’ degree in Biochemical Engineering from University College London.
Preeti Patel, GPI
I am clinical pharmacist with over 15 years of experience in pricing and reimbursement systems and solutions and have directed engagements throughout Europe, BRIC, and Asia, creating solutions to some of the most challenging business situations. I have led and directed teams on a variety of strategic and implementation projects and is passionate about helping companies resolve pricing challenges by championing the use of innovative solutions. I head up Global Pricing Innovations, GPI, who have a strategic partnership with P4A to support price modelling and competitor insights. Prior to setting up GPI, I worked as a VP at a US consulting firm heading up the global pricing practice.
Gianluca Funeri, GPI
I am a market access, pricing & health economics expert with 15 years’ experience in market access both from a strategic consulting and pharmaceutical industry perspective. I supported clients to define market access strategies for the launch of pharmaceutical products and medical devices. My key expertise lie within pricing and health economic modelling and I have supported clients in a number of projects focused on price-revenue optimization and on health technology assessment, cost-effectiveness analysis, and budget impact analysis.
Julie Brennan, Verto Health
As an associate to Partners4Access, I provide an in-depth understanding of the complex matrix that determines optimal market access in the U.K. I have spent the last 20 years working in the pharmaceutical industry as part of numerous commercialisation and launch execution teams and latterly as a consultant supporting clients to achieve the optimal access for their assets. I am passionate about bringing the strategy to life through excellence in HTA planning and implementation, value communications and payer-stakeholder engagement.
Anthony G. Bower, PhD, BRG LLC
I am president of the consultancy BRG LLC. The firm focuses on improving commercial effectiveness via insights and actions implemented at the executive level. The chief, but not only, focus for BRG in improving commercial effectiveness is by gaining and maintaining US and global market access. I have held industry leadership positions in the East Coast, California, and in Europe at, respectively, Synageva, ALZA and Amgen. In addition to over 10 years of experience in industry and several years in consulting, I spent a decade at RAND. My doctorate is in Economics from the Stanford Graduate School of Business.